Table 2

Tissue-specific multipotential stromal cell genes
Fold changing in expression between:
Gene HN/ICBM SF/ICBM HN/SF
ACAN Aggrecan 12.5 15.6 0.8
ALPL Alkaline phosphatase 4.8 6.4 0.8
BMP2 Bone morphogenetic protein 2 3.1 20.8 0.1
BMP4 Bone morphogenetic protein 4 3.2 5.6 0.6
BMPR1A Bone morphogenetic protein receptor, type IA 3.8 4.3 0.9
CEBPA CCAAT/enhancer-binding protein 11.4 19.1 0.6
COMP Cartilage oligomeric matrix protein 17.2 10.8 1.6
DAAM2 Disheveled associated activator of morphogenesis 2 2.9 2.2 1.4
FZD4 Frizzled family receptor 4 13.4 7.5 1.8
GATA2 GATA-binding protein 2 7.1 9.4 0.7
IGFBP3 Insulin-like growth factor-binding protein 3 11.8 21.3 0.6
OMD Osteomodulin 7.8 32.0 0.2
PPARG Peroxisome proliferator-activated receptor gamma 79.9 14.0 5.7
PRELP Proline/arginine-rich end leucine-rich repeat protein 19.1 87.1 0.2
SFRP4 Secreted frizzled-related protein 4 35.7 189.6 0.2
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 33.4 97.8 0.3
UGDH Uridine diphosphoglucose dehydrogenase 2.1 3.1 0.7

Relative fold change in expression identified as diagnostic for synovial fluid/Heberden’s node-multipotential stromal cells (SF/HN-MSCs) from statistical analysis (P ≤0.05, Mann-Whitney U). ICBM, normal iliac crest bone marrow.

Baboolal et al.

Baboolal et al. Arthritis Research & Therapy 2014 16:R119   doi:10.1186/ar4574

Open Data